TESARO Inc (NASDAQ:TSRO) CFO Timothy R. Pearson sold 2,575 shares of TESARO stock in a transaction that occurred on Friday, March 2nd. The shares were sold at an average price of $54.86, for a total transaction of $141,264.50. Following the sale, the chief financial officer now owns 7,303 shares in the company, valued at approximately $400,642.58. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
TESARO Inc (NASDAQ:TSRO) traded down $1.91 during mid-day trading on Wednesday, reaching $62.69. 782,411 shares of the company’s stock traded hands, compared to its average volume of 1,120,000. The company has a current ratio of 4.74, a quick ratio of 4.39 and a debt-to-equity ratio of 1.75. TESARO Inc has a 12-month low of $52.20 and a 12-month high of $171.80. The company has a market capitalization of $3,410.00, a price-to-earnings ratio of -6.83 and a beta of 1.40.
TESARO (NASDAQ:TSRO) last released its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($3.35) earnings per share for the quarter, missing the consensus estimate of ($2.39) by ($0.96). TESARO had a negative net margin of 222.15% and a negative return on equity of 126.44%. The business had revenue of $48.02 million for the quarter, compared to the consensus estimate of $51.78 million. equities research analysts predict that TESARO Inc will post -9.54 earnings per share for the current fiscal year.
A number of hedge funds have recently added to or reduced their stakes in TSRO. Nationwide Fund Advisors increased its stake in TESARO by 63.1% during the third quarter. Nationwide Fund Advisors now owns 61,500 shares of the biopharmaceutical company’s stock valued at $7,940,000 after purchasing an additional 23,800 shares during the last quarter. Crossmark Global Holdings Inc. bought a new stake in TESARO during the third quarter valued at $230,000. State Board of Administration of Florida Retirement System increased its stake in TESARO by 1.2% during the third quarter. State Board of Administration of Florida Retirement System now owns 49,054 shares of the biopharmaceutical company’s stock valued at $6,333,000 after purchasing an additional 570 shares during the last quarter. Ray Gerald L & Associates Ltd. bought a new stake in TESARO during the third quarter valued at $323,000. Finally, Gabelli Funds LLC bought a new stake in TESARO during the third quarter valued at $426,000.
A number of analysts have recently issued reports on the stock. BidaskClub upgraded shares of TESARO from a “sell” rating to a “hold” rating in a research note on Tuesday. Morgan Stanley dropped their price objective on shares of TESARO from $156.00 to $146.00 and set an “overweight” rating on the stock in a research note on Thursday, March 1st. ValuEngine upgraded shares of TESARO from a “sell” rating to a “hold” rating in a research note on Friday, March 2nd. Credit Suisse Group reiterated an “in-line” rating and set a $141.00 price objective (down previously from $150.00) on shares of TESARO in a research note on Wednesday, February 28th. Finally, Wells Fargo & Co reiterated an “outperform” rating and set a $122.00 price objective (down previously from $224.00) on shares of TESARO in a research note on Wednesday, February 28th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $133.39.
ILLEGAL ACTIVITY WARNING: “Timothy R. Pearson Sells 2,575 Shares of TESARO Inc (NASDAQ:TSRO) Stock” was reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://www.thelincolnianonline.com/2018/03/14/tesaro-inc-tsro-cfo-timothy-r-pearson-sells-2575-shares.html.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.